
$4.7B+29% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $4.7B in 2025, compounding +31% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $5.4B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
$-1.3BFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The company lost $1.3B in 2025, more than the $1.3B it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
+29.2%revenue growth, FY 2025
→Revenue grew +29% in 2025 against a five-year average of +54%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
$1.1B+23% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $1.1B in 2025, compounding +29% a year since 2022. That is the most cash the business has ever thrown off in a year. The trailing twelve months stand at $1.2B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Of $4.7B in 2025 sales, nothing survives to the bottom line - the journey ends $1.3B underwater.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→24 cents of every sales dollar became free cash in 2025, and it has held steady since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 42% of revenue (stock compensation 34%, capital spending 2%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→Operating margin widened 10 points to -31% since 2022. The bottom line is still negative: costs below the operating line eat what is left.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→ROE of -51% and ROCE of -30% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
21.9xP/S today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 21.9x sales, the market is paying 18% less than SNOW's own 6-year median of 26.5x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
1.0%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 1.0% of annual free cash flow, less than its 6-year median of 1.5% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Debt isn't clearly tagged in SNOW's filings, so treat the balance sheet with extra care rather than assuming zero.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→The company's own capital shrank from $5.2B in 2023 to $2.1B (-59%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Shareholders received $874M in buybacks in 2025. Stock compensation issued $1.6B of new shares in the same year, offsetting 100% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→The share count grew 1.4% in 2025, averaging 1.9% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→SNOW's return on capital is negative at -30.5% in 2025. The capital in the business is not yet earning anything back.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→SNOW issued +276% more shares from 2019 to 2025, but revenue per share still rose +370%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Insiders sold $424M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 7 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31